BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
BioCardia (NASDAQ:BCDA), a cardiovascular and pulmonary therapeutics developer, announces CEO Peter Altman's upcoming presentation at the H.C. Wainwright Global Investment Conference on September 10, 2025. The presentation will focus on three key areas: the company's clinical cell therapy programs for ischemic heart disease, regulatory progress for CardiAMP® cell therapy and Helix™ delivery catheter with FDA and Japan PMDA, and recent developments including the Heart3D fusion imaging partnership and CardiALLO program funding.
Dr. Altman will present at 2:00 PM ET at the Lotte Palace Hotel in New York City and will be available for one-on-one meetings with investors during the conference, which runs from September 8-10, 2025.
BioCardia (NASDAQ:BCDA), azienda specializzata in terapie cardiovascolari e polmonari, comunica che il CEO Peter Altman terrà una presentazione al H.C. Wainwright Global Investment Conference il 10 settembre 2025. L'intervento verterà su tre temi principali: i programmi clinici di terapia cellulare per la cardiopatia ischemica, i progressi regolatori relativi alla terapia cellulare CardiAMP® e al catetere di somministrazione Helix™ presso la FDA e la PMDA giapponese, e gli sviluppi recenti, tra cui la collaborazione per l'imaging fusion Heart3D e il finanziamento del programma CardiALLO.
Il dott. Altman parlerà alle 14:00 ET presso il Lotte Palace Hotel di New York e sarà disponibile per incontri individuali con gli investitori durante la conferenza, che si svolge dall'8 al 10 settembre 2025.
BioCardia (NASDAQ:BCDA), desarrolladora de terapias cardiovasculares y pulmonares, anuncia que su CEO Peter Altman presentará en la H.C. Wainwright Global Investment Conference el 10 de septiembre de 2025. La exposición se centrará en tres áreas clave: los programas clínicos de terapia celular para la enfermedad cardíaca isquémica, los avances regulatorios de la terapia celular CardiAMP® y el catéter de entrega Helix™ ante la FDA y la PMDA de Japón, y los desarrollos recientes, incluidos la asociación de imágenes fusionadas Heart3D y la financiación del programa CardiALLO.
El Dr. Altman presentará a las 2:00 PM ET en el Lotte Palace Hotel de Nueva York y estará disponible para reuniones uno a uno con inversores durante la conferencia, que se celebra del 8 al 10 de septiembre de 2025.
BioCardia (NASDAQ:BCDA)는 심혈관 및 폐 질환 치료제 개발사로서 CEO 피터 올트먼이 2025년 9월 10일 H.C. Wainwright Global Investment Conference에서 발표할 예정임을 발표합니다. 발표는 허혈성 심장질환 대상 임상 세포치료 프로그램, FDA 및 일본 PMDA 관련 CardiAMP® 세포치료와 Helix™ 전달 카테터의 규제 진행 상황, Heart3D 퓨전 이미징 협력 및 CardiALLO 프로그램 자금 조달 등 최근 개발 사항 등 세 가지 핵심 주제에 초점을 맞춥니다.
올트먼 박사는 뉴욕 Lotte Palace Hotel에서 동부시간 14:00(2:00 PM ET)에 발표하며, 2025년 9월 8일부터 10일까지 열리는 컨퍼런스 기간 중 투자자와의 1:1 미팅도 진행할 예정입니다.
BioCardia (NASDAQ:BCDA), développeur de traitements cardiovasculaires et pulmonaires, annonce que son CEO Peter Altman présentera lors de la H.C. Wainwright Global Investment Conference le 10 septembre 2025. L’intervention portera sur trois axes principaux : les programmes cliniques de thérapie cellulaire pour la maladie cardiaque ischémique, les progrès réglementaires concernant la thérapie cellulaire CardiAMP® et le cathéter de délivrance Helix™ auprès de la FDA et de la PMDA japonaise, ainsi que les développements récents, notamment le partenariat d’imagerie fusion Heart3D et le financement du programme CardiALLO.
Le Dr Altman présentera à 14h00 ET au Lotte Palace Hotel de New York et sera disponible pour des réunions individuelles avec des investisseurs durant la conférence, qui se tient du 8 au 10 septembre 2025.
BioCardia (NASDAQ:BCDA), ein Entwickler von Herz-Kreislauf- und pulmonalen Therapien, kündigt an, dass CEO Peter Altman am 10. September 2025 auf der H.C. Wainwright Global Investment Conference auftreten wird. Die Präsentation behandelt drei Schwerpunkte: die klinischen Zelltherapieprogramme bei ischämischer Herzkrankheit, regulatorische Fortschritte der Zelltherapie CardiAMP® und des Applikationskatheters Helix™ bei FDA und japanischer PMDA sowie aktuelle Entwicklungen wie die Heart3D-Fusionsbildpartnerschaft und die Finanzierung des CardiALLO-Programms.
Dr. Altman wird um 14:00 ET im Lotte Palace Hotel in New York City präsentieren und steht während der Konferenz, die vom 8. bis 10. September 2025 stattfindet, für Einzelgespräche mit Investoren zur Verfügung.
- None.
- None.
SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s President and CEO, Peter Altman, PhD., will present a corporate update, including recent progress toward milestones, at the H. C. Wainwright 27th Annual Global Investment Conference at the Lotte Palace Hotel in New York City.
Dr. Altman will present in person at 2:00 PM ET on Wednesday September 10, 2025. He will discuss the Company’s three clinical cell therapy programs for the treatment of ischemic heart disease and ongoing regulatory activities seeking FDA approval and Japan PMDA approval for CardiAMP® cell therapy for heart failure and its Helix™ transendocardial delivery catheter.
Dr. Altman will also detail the recent partnership to develop and commercialize Heart3D fusion imaging and the status of the nondilutive funding for the Company’s CardiALLO allogeneic mesenchymal stem cell program for the treatment of heart failure.
Dr. Altman will also be available for in person one-on-one meetings with investors.
The conference will be held from September 8-10, 2025 at the Lotte New York Palace Hotel. Dr. Altman’s presentation will be available for registered attendees via the conference platform. Conference attendees are invited to request one-on-one meetings via the conference portal, through their HCW representative, or directly with the Company through the investor contact email – investors@biocardia.com.
For more information about the H.C. Wainwright Global Investment Conference, please refer to the conference website at https://hcwevents.com/annualconference/.
Presentation Details:
- Date: September 10, 2025
- Time: 2:00 PM ET
- Location: Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY
- Speaker: Peter Altman, Ph.D., BioCardia’s President and CEO
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Marketing / Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
FAQ
When is BioCardia (BCDA) presenting at the H.C. Wainwright Conference 2025?
What topics will BioCardia's CEO discuss at the H.C. Wainwright Conference?
How can investors meet with BioCardia's management at the H.C. Wainwright Conference?
What are the main products BioCardia (BCDA) is seeking regulatory approval for?
